Sleep Quality in CHIMES (MF101)
Menopausal women often complain of difficulty sleeping and the transition from pre- to postmenopausal status is associated with an incresase in self-reported sleep disturbance. Hot flashes have been associated with self-reported measures of sleep disturbance and changes in sleep pattern as measured by plysomnography, including an increase in stage 4 and a latency or shortened time in rapid-eye movement sleep. Although there are some data on the effect of hormone replacement therapy on self-reported sleep measures in symptomatic postmenopausal women, there are no data on the effect of herbal extracts on subjective or objective measures of sleep quality in this population group. Actigraphy, the use of a device to record movement generally placed on the wrist, has been used over 20 years to provide objective data concerning sleep/wake patterns. The advantage of actigraphy over traditional polysomnography is that actigraphy can conveniently record continuously for 24-hours a day for longer periods of time.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
|Official Title:||Sleep Quality in CHIMES (MF101)|
- Actigraph watch (SleepWatch-O, Ambulatory Monitoring, Inc., Ardsley, NY)
|Study Start Date:||February 2006|
|Study Completion Date:||February 2007|
- To determine the effect of MF101 (a combination of Chinese herbs) compared to placebo on change in sleep quality utilizing baseline and follow-up actigraphy obtained from a subset of approximately 90 women enrolled in the randomized, double-blind, placebo-controlled Chinese Herbs for Menopausal Symptoms (CHIMES) trial.
- TO identify the correlates of sleep quality as assessed by actigraphy in women with frequent hot flashes. We will evaluate demographic, lifestyle, anthropometric, medical and gynecologic history and hormonal factors that may relate to the actigraphic measures of sleep quality, including self-reported measures of sleep.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00454441
|United States, California|
|University of California, San Francisco|
|San Francisco, California, United States|
|United States, Minnesota|
|University of Minnesota Twin Cities Campus|
|Minneapolis, Minnesota, United States, 55415|
|Principal Investigator:||Kristine Ensrud, MD, MPH||University of Minnesota Twin Cities Campus|